ATLASCoherus Oncology (CHRS) earnings date: Nov 9, 2026
Coherus Oncology (CHRS) reports earnings for the quarter ended Sep 30, 2026 on Mon, Nov 9, 2026, after the close. Analysts expect EPS of -$0.22.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on CHRS
| Last price | $0.76 (-8.9%) |
|---|---|
| Normal 1-day range (±1σ) | ±6.6% |
| Earnings beat history | Beat the EPS estimate in 1 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Coherus Oncology stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Coherus Oncology reports on Nov 9, 2026. One email the day before, with ATLAS’s read on Coherus Oncology. You can switch it off at any time.
Alert me before CHRS reportsFree to start. Creating an account takes under a minute.
Notify me when Coherus Oncology reports
Track CHRS free Add Coherus Oncology to a free ATLAS watchlist and see its next report date in one place.
CHRS earnings at a glance
| Next report (confirmed) | Mon, Nov 9, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.22 |
| Last report | Aug 5, 2026 · Miss |
| Beat rate (last 5 reports) | 1 of 5 (20%) |
| Average EPS surprise | -14.9% |
| Average move around a report | ±6.1% (last 5) |
| Sector | Healthcare · Biotechnology |
Coherus Oncology earnings history: last 5 reports
Coherus Oncology last reported on Aug 5, 2026: EPS of -$0.19 against an estimate of -$0.11 (-72.7% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 5, 2026 | -$0.11 | -$0.19 | -72.7% | Miss | -14.5% |
| Jul 18, 2026 | $0.39 | $0.38 | -2.6% | Miss | +5.0% |
| May 11, 2026 | -$0.26 | -$0.25 | +3.8% | Beat | -2.3% |
| Mar 9, 2026 | -$0.33 | -$0.34 | -3.0% | Miss | +7.1% |
| Nov 17, 2025 | $4.76 | $4.76 | 0.0% | In line | +1.7% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for CHRS
See the fair value, the probability range and the earnings history of Coherus Oncology on its ATLAS page.
Coherus Oncology (CHRS) stock analysisPlans from €3.99 a month.
Coherus Oncology earnings: frequently asked questions
When does Coherus Oncology (CHRS) report earnings?
Coherus Oncology is scheduled to report on Monday, November 9, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for CHRS?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.22 per share (USD). Estimates can change before the report.
How often does CHRS beat earnings estimates?
Of its last 5 reports with a recorded result, Coherus Oncology beat the EPS estimate 1 times; the average surprise was -14.9%. Past results do not predict the next one.
How much does CHRS move around earnings?
Over its last 5 reports the stock moved an average of 6.1% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did Coherus Oncology beat earnings estimates last quarter?
Coherus Oncology last reported on Aug 5, 2026: EPS of -$0.19 against an estimate of -$0.11 (-72.7% surprise), a miss.
How much does CHRS usually move in a day?
On a normal trading day the ATLAS model puts CHRS’s one-day range at about ±6.6%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Mon, Nov 9, 2026
Educational information, not investment advice. Disclaimer